Brind.
  1. Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE.

Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.

2 reports, 1 independent Updated Sep 9
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amgen and AstraZeneca co-developed the severe asthma drug TEZSPIRE, prompting an analyst to raise the price target.

Who's involved

What this event is mainly about
AmgenAstraZeneca

Keep exploring

Part of

Amgen and AstraZeneca partnered on a Phase 3 CROSSING trial for the drug TEZSPIRE. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story